These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33818029)

  • 21. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A surface-free design for phase I dual-agent combination trials.
    Mozgunov P; Gasparini M; Jaki T
    Stat Methods Med Res; 2020 Oct; 29(10):3093-3109. PubMed ID: 32338145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shift models for dose-finding in partially ordered groups.
    Horton BJ; Wages NA; Conaway MR
    Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Competing designs for drug combination in phase I dose-finding clinical trials.
    Riviere MK; Dubois F; Zohar S
    Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Ci3+3 design for dual-agent combination dose-finding clinical trials.
    Yuan S; Zhou T; Lin Y; Ji Y
    J Biopharm Stat; 2021 Nov; 31(6):745-764. PubMed ID: 34781853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology.
    Takeda K; Zhu J; Li R; Yamaguchi Y
    Pharm Stat; 2023; 22(6):1104-1115. PubMed ID: 37545018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials.
    Lin R; Yin G; Shi H
    Biostatistics; 2023 Apr; 24(2):277-294. PubMed ID: 34296266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
    Zang Y; Lee JJ
    Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian optimal interval design for dose finding in drug-combination trials.
    Lin R; Yin G
    Stat Methods Med Res; 2017 Oct; 26(5):2155-2167. PubMed ID: 26178591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
    Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
    Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
    Chen X; Zhang J; Jiang Q; Yan F
    J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementing and assessing Bayesian response-adaptive randomisation for backfilling in dose-finding trials.
    Pin L; Villar SS; Dehbi HM
    Contemp Clin Trials; 2024 Jul; 142():107567. PubMed ID: 38729298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consistency of the CRM when the dose-toxicity curve is not monotone and its application to the POCRM.
    Saha PT; Fine JP; Ivanova A
    Stat Med; 2021 Apr; 40(8):2073-2082. PubMed ID: 33588519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
    Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
    Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation.
    Xu J; Zhang D; Mu R
    BMC Med Res Methodol; 2022 Oct; 22(1):258. PubMed ID: 36183071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials.
    Li Z; Xu Z; Zhang A; Qi G; Li Z
    BMC Med Res Methodol; 2023 Mar; 23(1):57. PubMed ID: 36864387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
    O'Connell NS; Wages NA; Garrett-Mayer E
    Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.